Want to see SG:H02 full AI Analyst Report?
Haw Par (H02) AI Stock Analysis
Haw Par
(SGX:H02)
The score is driven primarily by strong financial strength (very low leverage and strong 2025 cash generation), partially offset by a 2025 revenue decline and lower earnings-quality confidence due to unusually high net margins. Technical indicators are neutral-to-soft, while valuation is supportive with a moderate P/E and a solid dividend yield.
Haw Par (H02) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- SGD 2.39B
- Dividend Yield
- 3.09%
- Average Volume (3M)
- 276.41K
- Price to Earnings (P/E)
- 12.5
- Beta (1Y)
- 0.70
- Revenue Growth
- -13.24%
- EPS Growth
- -8.48%
- Country
- Singapore
- Employees
- 595
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Haw Par Business Overview & Revenue Model
Company Description
Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business...
How the Company Makes Money
Haw Par makes money mainly through (1) consumer healthcare product sales and (2) income from its leisure/attractions activities, with additional contributions from (3) returns on its investment holdings. 1) Consumer healthcare (core operating revenue...
Haw Par Financial Statement Overview
Summary
Very strong balance sheet with extremely low leverage (debt-to-equity ~0.01) and solid financial flexibility. Cash flow improved sharply in 2025 with strong free cash flow and good cash-to-earnings alignment (~0.99x), but earlier years showed weaker cash conversion. Revenue declined in 2025 (-9.12%) and unusually high net margins (often near/above 100%) suggest non-operating items may be driving earnings, reducing confidence in repeatability.
Income Statement
74PositiveBalance Sheet
92Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 219.55M | 229.97M | 244.82M | 232.06M | 182.09M | 141.18M |
| Gross Profit | 121.94M | 128.76M | 134.09M | 134.89M | 98.57M | 73.64M |
| EBITDA | 73.32M | 73.45M | 250.11M | 233.49M | 49.06M | 119.45M |
| Net Income | 229.19M | 265.46M | 228.27M | 216.57M | 148.32M | 110.10M |
Balance Sheet | ||||||
| Total Assets | 4.88B | 4.42B | 4.28B | 3.59B | 3.65B | 3.28B |
| Cash, Cash Equivalents and Short-Term Investments | 881.34M | 834.71M | 3.93B | 3.21B | 3.18B | 596.23M |
| Total Debt | 52.60M | 44.27M | 36.30M | 28.48M | 58.40M | 1.52M |
| Total Liabilities | 133.88M | 126.83M | 128.47M | 117.17M | 101.41M | 72.08M |
| Stockholders Equity | 4.74B | 4.29B | 4.15B | 3.48B | 3.55B | 3.21B |
Cash Flow | ||||||
| Free Cash Flow | 224.94M | 269.17M | 50.33M | 54.92M | 21.21M | 14.46M |
| Operating Cash Flow | 227.34M | 271.29M | 53.79M | 62.68M | 40.94M | 18.84M |
| Investing Cash Flow | -187.29M | 76.93M | 199.82M | 258.00M | -261.58M | 87.52M |
| Financing Cash Flow | -70.80M | -300.68M | -82.79M | -79.30M | -38.07M | -65.11M |
Haw Par Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:H02, the sentiment is Neutral. The current price of 12.86 is below the 20-day moving average (MA) of 12.89, below the 50-day MA of 13.43, and below the 200-day MA of 15.42, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 62.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SG:H02.
Haw Par Peers Comparison
Overall Rating
- SG:H0274Outperform
SG:BSL66Neutral
SG:A5048Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SG:H02 | 74Outperform | SGD 2.87B | 12.46 | 5.07% | 3.09% | -13.24% | -8.48% |
| SG:BSL | 66Neutral | SGD 1.55B | 22.40 | 6.42% | 3.66% | -3.18% | 6.71% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SG:A50 | 48Neutral | SGD 1.27B | -41.13 | -6.42% | ― | 6.44% | 38.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:H02 | Haw Par Corporation | 12.96 | -1.81 | -12.28% | |
| SG:BSL | Raffles Medical Group | 0.82 | -0.14 | -14.94% | |
| SG:A50 | Thomson Medical Group Ltd. | 0.05 | -0.01 | -18.64% | |
| SG:1J5 | Hyphens Pharma International Ltd. | 0.36 | 0.01 | 3.15% | |
| SG:40T | ISEC Healthcare Ltd | 0.31 | -0.02 | -6.91% | |
| SG:546 | Medtecs International Corporation Ltd. | 0.10 | -0.02 | -17.74% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 04, 2026